A Phase 1, Randomized, Double-blind, Sponsor-open, Placebo-controlled, First-in-human Trial To Evaluate The Safety, Tolerability, And Pharmacokinetics Of Pf-06755347 After Single Ascending Intravenous Infusions To Healthy Adult Subjects
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 12 Feb 2018
At a glance
- Drugs PF-06755347 (Primary)
- Indications Chronic inflammatory demyelinating polyradiculoneuropathy
- Focus Adverse reactions; First in man
- Sponsors Pfizer
- 07 Feb 2018 Planned End Date changed from 30 Dec 2019 to 13 Nov 2019.
- 07 Feb 2018 Planned primary completion date changed from 30 Dec 2019 to 13 Nov 2019.
- 26 Jan 2018 Planned End Date changed from 30 Dec 2018 to 30 Dec 2019.